Latest Regulated Markets News

Althea Group Holdings announces the immediate resignation of founder and CEO Joshua Fegan, appointing Barry Katzman as interim CEO to steer the company’s THC beverage growth in North America.

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

EVE Health Group has successfully passed all shareholder resolutions at its recent General Meeting, paving the way for its acquisition of Nextract Pty Ltd and announcing significant leadership changes.

Matsa Resources has advised shareholders to take no immediate action following Patronus Resources’ unsolicited takeover offer, with a formal recommendation expected soon.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Constellation Technologies reports a slight decline in quarterly sales but marks a strategic breakthrough by deploying its Callisto Food Safety & Compliance system into the Aged Care sector, positioning itself for growth in a highly regulated market.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.